Market Overview:
The global antacids market size reached US$ 6.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4% during 2023-2028.
Antacids are over-the-counter (OTC) medications that neutralize the acid in the stomach to relieve indigestion and heartburn. They contain ingredients such as sodium bicarbonate, aluminum, magnesium hydroxide, and calcium and are commonly available in convenient chewable tablets, powder, and liquid forms. Antacids are widely used for treating sore stomach, dyspepsia discomfort, stomach ulcers, inflammation, acid indigestion, and stomach upset. Acid neutralizers, promotility agents, and proton pump inhibitors are common drugs that weaken the acid in the stomach. They assist in protecting the stomach lining from the duodenum, esophagus, and harsh acids released while eating. They are self-prescribed medications and act by neutralizing the acid in the stomach and inhibiting pepsin.
-(1).webp)
Antacids Market Trends:
The increasing prevalence of gastroesophageal reflux diseases (GERD) is one of the key factors driving the growth of the market. Antacids are widely used as they are cost-effective and assist in relieving inflammation, swelling, pain, and irritation associated with heartburn. In line with this, changing lifestyles, such as irregular dietary habits, sleep patterns, and sedentary lifestyles, is positively impacting the market growth. Moreover, various product innovations, such as the development of raft-forming antacids that are safe and strong medications that provide higher efficacy and increased duration of action, are providing an impetus to the market growth. Additionally, the widespread adoption of chewable tables in different flavors that are easy to store, provide the correct amount of dosage, and improve patient adherence is favoring the market growth. Other factors, such as the rising geriatric population that are prone to acidic complications, easy product availability through e-commerce platforms, and the increasing prevalence of heartburn among the masses, are creating a positive outlook for the market.
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global antacids market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, formulation type and distribution channel.
Breakup by Drug Class:
- Proton Pump Inhibitors
- H2 Antagonist
- Acid Neutralizers
- Pro-Motility Agents
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Breakup by Formulation Type:
- Tablet
- Liquid
- Powder
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2022 |
Historical Period |
2017-2022 |
Forecast Period |
2023-2028 |
Units |
US$ Billion |
Segment Coverage |
Drug Class, Formulation Type, Distribution Channel, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |